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Evidence is increasing that Zika virus–related adverse 
outcomes can occur throughout pregnancy. Mathematical 
modeling analysis using reported outcome data suggests 
that surveillance for these outcomes should begin as soon 
as an outbreak is detected and should continue for 40 
weeks after the outbreak ends.
Quantifying the risk for adverse pregnancy outcomes (APOs) after Zika virus infection is of critical public 
health importance. Recent studies have suggested that risk 
for microcephaly is concentrated in pregnancies in which 
infection occurs during the first trimester (1,2). However, 
microcephaly is at the severe end of the APO spectrum and 
might have a different risk profile from other outcomes: 
brain abnormality and malformation, eye anomalies, neural 
tube defects, arthrogryposis, congenital deafness, and oth-
ers (3). In particular, estimates of APOs after symptomatic 
confirmed Zika virus infection suggest risk for fetal injury 
throughout pregnancy (3,4). Thus, a better understanding 
of the likely duration and risk for APOs after Zika virus 
outbreaks is urgently needed (2). We used surveillance and 
clinical data to estimate the timing and number of expected 
APO events after observed Zika outbreaks in 9 regions of 
Brazil during April 2015–July 2017.
The Study
To quantify APO risk, we used data from a study that re-
cruited 345 pregnant women with rash in the previous 5 
days, of whom 134 tested positive for Zika virus infec-
tion (4). Excluding 9 losses to follow-up, we followed a 
cohort of 125 women during pregnancy; surviving infants 
were examined for APOs. A total of 58 APOs occurred in 
this group; microcephaly was infrequent (4 [6.9%] of 58) 
but severe (4).
We fitted a logistic model to individual-level data for 
the 125 followed-up women to estimate the proportion of 
APOs after symptomatic Zika virus infection at each week 
of gestation (Figure 1, panel A). Although the fitted linear 
model suggested a decline in risk over time, the model did 
not perform significantly better than a model with constant 
risk for APO at any gestational age (online Technical Ap-
pendix, https://wwwnc.cdc.gov/EID/article/24/1/17-0482-
Techapp1.pdf). For comparison, we also considered a theo-
retical risk profile in which APO risk occurs only during 
the first trimester (Figure 1, panel A).
We used these risk profiles to estimate the period 
through which an elevated rate of APOs would be expected 
after the 2015–2016 Zika epidemic in 9 regions of Brazil 
(Figure 1, panels B–J). We superimposed the timing of 
confirmed microcephaly cases in each region to assess the 
relationship between observed microcephaly and expected 
duration of elevated APO risk but did not fit explicitly to 
microcephaly incidence data. If risk were assumed to occur 
only during the first trimester, the period of APOs would be 
shorter than the duration of observed microcephaly events. 
In contrast, the predicted durations of APOs based on risk 
throughout pregnancy were more consistent with the ob-
served distribution of microcephaly in these regions.
To examine the potential duration and risk for Zika-
associated APOs more generally, we also predicted the 
pattern of APOs under 3 hypothetical epidemic scenarios: 
single outbreak, multipeaked epidemic, and endemic trans-
mission (Figure 2). For each epidemic scenario, the model 
suggested that the duration of elevated risk was much lon-
ger than the duration of cases if APOs could occur from 
infection in any gestational week. This observation means 
that in areas where seasonal outbreaks of Zika occur, the 
risk for APOs might not return to baseline levels between 
epidemics, and Zika-specific interventions based on timing 
of pregnancy might be less effective (7).
Our findings are subject to several limitations. First, 
we based the estimation of APO risk by gestation period on 
a cohort study of symptomatic infection with rash, which 
does not occur with all Zika virus infections (8). However, 
recent evidence suggests the risk for APOs is similar for 
symptomatic and asymptomatic infection (9). We included 
pregnancy loss during the first trimester (miscarriage) as an 
APO, but excluding these 5 cases did not alter the findings 
(online Technical Appendix, Sensitivity Analysis on Inclu-
sion of Miscarriages section). Moreover, evidence suggests 
that APOs might not be detectable at birth but appear later, 
which would underestimate the frequency of APOs (10).
Second, the data were from patients recruited in Rio de 
Janeiro, whereas we considered potential risk across all re-
gions of Brazil. Although the cohort was large and APO data 
detailed, numbers of exposed women in each gestational 
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week were low, leading to large CIs on the risk profile (Fig-
ure 1, panel A). We therefore used a linear model to estimate 
the risk at each gestational week because data were insuf-
ficient to fit a more complex risk function. The range of data 
(6–39 weeks’ gestation) also constrained our estimates.
Third, publicly available epidemiologic reports from 
Brazil recorded microcephaly cases, rather than all forms 
of APO. We qualitatively compared these microcephaly re-
ports with our estimates for the duration of risk for APOs, 
but the risk for microcephaly by gestational week might 
differ from the overall risk for APOs. Different regions 
are likely to have differing baseline levels of APOs in the 
absence of Zika virus infection; we therefore focused our 
analysis on the risk for APOs associated with Zika virus 
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Figure 1. Relationship between Zika virus infection and expected related APOs per 1,000 pregnancies in Brazil during April 2015–July 2017. 
A) Percentage of APOs (fetal loss at any gestational age, stillbirth, neonatal abnormality) given symptomatic PCR-confirmed Zika virus 
infection. Points show weekly proportion with APO (4); red line indicates fit to data with a generalized linear model, and shading indicates 
95% CIs; dashed line indicates fixed risk in first trimester only (5). B–J) Blue lines indicate suspected Zika cases in different regions; red 
lines indicate expected number of births with Zika-associated APO in subsequent weeks based on the 2 risk distributions in panel A.  
Shaded regions indicate 95% CIs. Model assumes 17% of Zika virus infections are reported (5,6). APO, adverse pregnancy outcome.
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infection. Why some areas of Latin America have reported 
more cases of microcephaly than others remains unclear 
(11). There may be unmeasured cofactors that alter the risk 
for APO on Zika virus infection (12). Another factor could 
be differences in the proportion of Zika cases reported, 
which could lead to variation in incidence of APOs. We 
assumed 17% of Zika infections were reported (6,8); if the 
proportion reported was larger, it would mean fewer women 
were infected during the epidemic, and hence fewer would 
be expected APOs (online Technical Appendix, Sensitivity 
Analysis on Fraction of Cases Reported section).
Finally, Brazil made Zika notifiable in November 2015, 
which might have increased reporting (13). In addition, the 
Zika incidence data varied markedly by region, which may 
be due to true differences in outbreak dynamics or to differ-
ences in reporting of cases (Figure 1). Although variability in 
weekly Zika incidence data would alter the precise relation-
ship between Zika cases and population-level rate of APO, 
the general shape and duration of enhanced risk estimated 
in the model remains the same (online Technical Appendix, 
Sensitivity Analysis on Fraction of Cases Reported section).
Conclusions
Our results suggest that if fetal injury from Zika virus 
infection can occur across a range of gestational ages, 
APOs after a Zika outbreak could occur for a long time 
after the outbreak subsided. This duration is longer than if 
the risk is assumed to be in the first trimester only (2,14). 
Combined with epidemiologic reports of APOs collected 
in Brazil, which show an increase in microcephaly rate 
at a time inconsistent with first trimester–only risk, evi-
dence is mounting to recommend extended surveillance 
for APOs and to include a spectrum of outcomes, not only 
microcephaly (10,15).
Our results suggest that when Zika outbreaks are 
identified, surveillance and planning for infection-associ-
ated APOs might need to focus on a longer period than 
previously thought. In addition to the potential for APOs 
several months after an epidemic, the risk period may 
begin soon after the outbreak is detected. Further studies 
are crucial to refine the risk for APO during gestation and 
to ensure pregnant women can be correctly informed of 
their risk, so that population-level surveillance can be ef-
fectively implemented.
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etymologia revisited
Zika Virus
Zika [zēk′ ə] Virus
Zika virus is a mosquito-borne,  positive-sense, single-stranded RNA virus in the family Flaviviridae, genus Flavivirus that causes a mild, acute febrile 
illness similar to dengue. In 1947, scientists researching yellow fever placed a 
rhesus macaque in a cage in the Zika Forest (zika meaning “overgrown” in the 
Luganda language), near the East African Virus Research Institute in Entebbe, 
Uganda. A fever developed in the monkey, and researchers isolated from its se-
rum a transmissible agent that was first described as Zika virus in 1952. It was 
subsequently isolated from a human in Nigeria in 1954. From its discovery until 
2007, confirmed cases of Zika virus infection from Africa and Southeast Asia 
were rare. In 2007, however, a major epidemic occurred in Yap Island, Microne-
sia. More recently, epidemics have occurred in Polynesia, Easter Island, the Cook 
Islands, and New Caledonia.
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